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Abstract
We describe the case of a 57 year-old woman with NSTE ACS, a history of recurrent and
prolonged epistaxis, and low prior cardiovascular risk. Additional findings revealed anemia
and an aneurysm in her central nervous system. During her hospital stay, hereditary
hemorrhagic telangiectasia (HHT) was diagnosed. After application of two antiplatelet drugs,
the patient was scheduled for coronarography, followed by coronary artery bypass grafting.
During her hospital stay, only a minor episode of epistaxis was observed. We conclude that
anemization due to HTT may significantly accelerate the progress of ischemic heart disease,
resulting in acute coronary syndrome. Moreover, coronarography preceded by routine applica-
tion of two antiplatelet drugs seems not to increase the risk of hemorrhage in HHT patients
complicated with myocardial infarction. (Cardiol J 2010; 17, 2: 189–191)
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Hereditary hemorrhagic telangiectasia (HHT)
is an autosomal dominant systemic fibrovascular
dysplasia in which telangiectases, arteriovenous
malformations, and aneurysms may be widely distrib-
uted throughout the body vasculature [1]. It affects
approximately 1 in 8000 individuals worldwide [2], and
cuts life expectancy by approaching seven years [3].
Major clinical manifestations include recurrent
bleeding from mucosal telangiectases and arterio-
venous malformations [1]. Epistaxis is the most fre-
quent first clinical symptom and usually develops
before the age of 20 [4]. However, age of onset and
severity are highly variable. Patients may not be
diagnosed until a life-threatening complication is
presented.
We are presenting a case of myocardial infarc-
tion (MI) in a patient with HHT.
A 57 year-old woman with negative past medical
and family history was admitted for chest pain and
suspicion of Non-ST Elevation Acute Coronary Syn-
drome (NSTE ACS). She was a non-obese non-smok-
er who had never received substitutive hormonal the-
rapy or any other medical treatment. However, she
reported a one week history of progressive chest pain
(initially only at exertion, then also at rest) and a two
month history of recurrent and prolonged epistaxis.
Electrocardiography on admission revealed ST
depression in the inferior leads and transient ST
elevation in the leads V1–V3. Over the following
days, negative T waves in all chest leads developed.
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Laboratory findings displayed serum troponin eleva-
tion only in the third sample (the prior two samples
were within normal limits), microcytic anaemia
— Hgb 8 g%, Htc 26%, MCV 62 FL, Fe 16 µg/dL,
UIBC 324 µg/dL.
According to risk stratification, an early con-
servative strategy was applied. Therefore, two units
of packed red blood cells were transfused, achieving
satisfactory improvement. Physical examination re-
vealed multiple angiomas in the epithelium of naso-
pharynx (Fig. 1) which enabled diagnosis of HHT.
Applied treatment involved: clopidogrel, acetil-
salicilic acid (ASA), metoprolol, perindopril, simv-
astatin, oral folic acid and iron supplements.
Magnetic resonance imaging, performed to
assess potential malformation in the central nerv-
ous system, displayed a 2 mm aneurysm of the left
posterior communicating artery (Fig. 2). Initially,
echocardiography revealed hypokinesis of the an-
terior wall and interventricular septum, accompa-
nied by slight mitral and tricuspid insufficiency with
left ventricular ejection fraction of 55%. However,
all symptoms of contractility disorders withdrew
before discharge.
Coronary angiography revealed multilevel cri-
tical stenoses in the medial and distal portion of the
left anterior descending (LAD) artery with the os-
tium of the second diagonal branch involvement
(Fig. 3). The patient underwent left internal mam-
mary artery (LIMA)-LAD off pump coronary artery
bypass grafting followed by coronary artery bypass
grafting to diagonal artery. The patient, with good
early post-operative results, was transferred to
another unit for further rehabilitation.
Acute coronary syndrome (ACS) risk model
according to GRACE at admission revealed a 1%
probability of death during hospital stay, and 6%
within six months. The risk of in-hospital death or
death/MI reached 14% and 21% in a six month ho-
rizon. The TIMI risk score was three (moderate).
At discharge, the six month risk dropped to 1%
for death and 2% for death or MI, which we consid-
ered satisfactory.
Myocardial infarction frequently (in 50–70% of
cases) appears as the first manifestation of ischemic
heart disease [5, 6], especially in normotensive [6]
young males and often is associated with impair-
ment of a single vessel [7, 8]. Our patient seemed
Figure 1. Angiomas in lower lip.
Figure 2. Aneurysm of left posterior communicating
artery.
Figure 3. Narrowings in left anterior descending.
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to have experienced progression from stable angi-
na to NSTE ACS within one week. Nevertheless,
apart from anemisation, which also is a significant
and independent predictor of major adverse cardi-
ovascular events in ACS patients [9], she had no
other risk factors.
Baseline hemoglobin level of 8–9 g/dL at ad-
mission in NSTE patients is associated with a 2.45
(95% confidence interval 1.80–3.33) fold increase
in 30-day risk of cardiovascular death, MI or recur-
rent ischemia [9]. Therefore, we decided to trans-
fuse 2 units of packed red blood cells. However, it
has also been proved that in such patients blood
transfusion may contribute to in-hospital death or
MI with estimated odds ratio 1.44 (95% confidence
interval 1.30–1.60) [10].
The application of two antiplatelet drugs is
a routine management of patients scheduled for co-
ronarography. Due to the increased risk of bleeding
in HTT patients, particularly with intracranial an-
eurysm, we were concerned about applying the
second antiplatelet drug. Acute complications con-
sidering heart and ischemic stroke were evaluated
respectively at 4.3% and 7.5% [11]. Literature pro-
vided us with one interesting, but only partially
relevant, case report, which was not enough to sup-
port a clear clinical decision. The reported patient
was a middle-aged woman with NSTE and previous-
ly diagnosed HHT treated only with acetyl salicyl-
ic acid [12]. Nevertheless, we decided to combine
ASA with clopidogrel and during the hospital stay
we observed only one episode of minor epistaxis.
We also observed an interesting evolution of
cTnT levels (Fig. 4). The increase was relatively
late and very transient, which in association with
echocardiographic findings may be considered a re-
sult of minor subendocardial ischemia. Moreover,
some studies indicate that stored blood may promote
vasoconstriction and trigger ischemic events [13].
It is probable that accelerated progression of
angina resulting in ACS was caused by decompen-
sation due to recurrent blood loss (first clinical
manifestation of HHT) in combination with pre-
existing multilevel narrowings in LAD. Human he-
reditary telangiectasia may sometimes be revela-
tory for ischemic heart disease but does not seem
to require major changes in the standard manage-
ment of ACS.
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